ESTRO 2024 - Abstract Book

S1172

Clinical - Haematology

ESTRO 2024

As adverse events, only 2 patients experienced acute epitheliolysis during TSEBI, graded 2 and 3 according to CTCAE score and resolved at the first follow-up visit.

Conclusion:

In our cohort, despite the small number of patients and the adverse clinical characteristics, TSEBI appears to be a potential and useful treatment strategy for palliation at relapse after AT in MF/SS patients. In our experience higher doses could be required in order to obtain a durable response in this unfavorably selected patient cohort.

Keywords: cutaneous lymphoma

2797

Digital Poster

Initial Clinical and Dosimetric outcomes with TBI planned on Helical Tomotherapy

Varghese Antony

RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE, RADIATION ONCOLOGY, DELHI, India

Purpose/Objective:

To present our treatment technique, dosimetric results, and our first clinical data for patients receiving total body irradiation on Helical Tomotherapy as part of the conditioning regimen before hematopoietic stem cell transplantation and describe the challenges faced and their solutions developed from simulation to implementation1.

Material/Methods:

The cohort consisted of 45 patients who were treated in our institution between March 2022 and September 2023. The total dose and fractionation prescribed was as per protocol issued by the Department of haemato-oncology. The dose distribution information in the treatment volumes, and area of junctions were tabulated and analyzed. The challenges faced from simulation to implementation and their solutions are described from radiation oncologist perspective. Clinical outcomes and events after the procedure were collected from medical records.

Results:

Median age was 28.4 years (range, 2 – 59 years). Total dose prescribed ranged from 2Gy to 12Gy. Simulation issues were resolved with various setup devices tailored to patient’s physical parameters and comfort. Dosimetric parameters were achieved in agreement with published guidelines, including the junctional doses with acceptable CI, HI and QRTOG. Setup was adequately implemented on treatment couch with minimum corrections. All patients